2025-07-24
39 分钟Welcome to Huberman Lab Essentials,
where we revisit past episodes for the most potent and actionable science-based tools for mental health,
physical health, and performance.
I'm Andrew Huberman,
and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine.
And now my conversation with Dr. Matthew Johnson.
Well, Matthew, I've been looking forward to this for a long time.
I'm a huge fan of your scientific work and I'm eager to learn from you.
Likewise, big fan and happy to do this with you.
Great.
Well, thank you.
My first question is a very basic one, which is what qualifies a substance as a psychedelic?
Nomenclature is a real challenge in this area of psychedelics.
So starting with the word psychedelic, it just, if you're a pharmacologist,
it's not very satisfying because that term really spans different pharmacological classes.
In other words,
if you're really concerned about receptor effects and the basic effects of a compound,
it spans several classes of compounds.
But overall, so it's really more of a cultural term or it does have a relationship to drug effects,
but it's at a very high level.